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ABSTRACT
Deregulation of proliferation and differentiation-dependent signalling pathways 
is a hallmark of human papillomavirus (HPV) infection. Although the manipulation of 
these pathways by E6 and E7 has been extensively studied, controversies surround 
the role of the E5 oncoprotein during a productive virus life cycle. By integrating 
primary keratinocytes harbouring wild type or E5 knockout HPV18 genomes with 
pharmacological and gain/loss of function models, this study aimed to provide 
molecular information about the role of E5 in epithelial proliferation and differentiation. 
We show that E5 contributes to cell cycle progression and unscheduled host DNA 
synthesis in differentiating keratinocytes. E5 function correlates with increased EGFR 
activation in differentiating cells and blockade of this pathway impairs differentiation-
dependent cell cycle progression of HPV18 containing cells. Our findings provide 
a functional requirement of enhanced EGFR signalling for suprabasal cellular DNA 
synthesis during the virus life cycle. They also reveal an unrecognised contribution 
of E5 towards the impaired keratinocyte differentiation observed during a productive 
HPV infection. E5 suppresses a signalling axis consisting of the keratinocyte growth 
factor receptor (KGFR) pathway. Inhibition of this pathway compensates for the 
loss of E5 in knockout cells and re-instates the delay in differentiation. The negative 
regulation of KGFR involves suppression by the EGFR pathway. Thus our data reveal 
an unappreciated role for E5-mediated EGFR signalling in orchestrating the balance 
between proliferation and differentiation in suprabasal cells.
INTRODUCTION
Human papillomaviruses (HPV) infect the 
squamous epithelial cells at a number of body sites [1, 2]. 
A small number of HPV types are carcinogenic and 
recognized as the agent for most anogenital cancers and a 
subset of cancers of the oropharyngeal tract, with HPV16 
and HPV18 being responsible for the largest incidence of 
cervical cancer [3, 4].
Keratinocyte homeostasis is controlled by the 
complex interplay of signalling pathways functioning 
in an integrated fashion. In the basal compartment, 
epidermal growth factor receptor (EGFR) signalling 
is a major determinant of keratinocyte proliferation by 
promoting cell cycle progression [5]. Tissues lacking key 
components of the EGFR signalling pathway including 
ERK/MAPK are hypoproliferative and display G2/M 
arrest [5]. In addition to increasing proliferation, EGFR 
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signalling suppresses keratinocyte differentiation [6]. This 
is required to maintain homeostasis between self-renewing 
and committed keratinocytes in the basal proliferative 
compartment of the epidermis, whereas in the upper 
layers this pathway is down regulated. Once a keratinocyte 
enters the suprabasal layer, it induces expression 
of proteins involved in the sequential programme 
of terminal differentiation [7]. Whilst there is not a 
complete understanding of the pathways that orchestrate 
differentiation, a number of critical regulators of this 
process are recognized including the keratinocyte growth 
factor receptor (KGFR/FGFR2IIIb). This is expressed in 
suprabasal layers and induces gene expression changes 
associated with terminal differentiation. KGFR over-
expression in basal cells induces premature expression 
of spinous layer associated markers, whilst ablation, by 
genetic or chemical means, results in a hyperproliferative 
epidermis [8, 9].
The HPV life cycle is linked to differentiation of 
the epithelial tissues they infect. Following infection of 
keratinocytes in the epithelial basal layer, HPV genomes 
are established as episomes. After a mitotic event, infected 
basal cells migrate towards the suprabasal regions 
and begin to differentiate. In contrast to uninfected 
keratinocytes, when the infected basal cells detach from 
the basement membrane they fail to undergo the early 
stages of differentiation and re-enter the cell cycle in 
the suprabasal layers to enable the virus episomes to be 
amplified to a high copy number [1]. In the upper layers 
of the epithelium, infected cells exit the cell cycle and re-
enter the differentiation process, enabling transit to the late 
stage of infection, where the late promoter is activated to 
drive expression of the structural proteins in preparation 
for packaging of the viral genome into newly synthesized 
capsids.
High-risk HPV genomes encode three early genes 
(E5, E6 and E7), classed as oncogenes that manipulate the 
host cell environment by influencing cell proliferation, 
differentiation and survival. E6 and E7 are the major 
drivers of keratinocyte proliferation and their expression is 
retained in cancers. They are required for immortalization 
of keratinocytes and their best understood functions are to 
inactivate p53 and pRb tumour suppressor proteins [10, 
11]. In contrast, E5 remains one of the least understood 
of the early proteins [12]. E5 is a membrane-integrated 
protein [12, 13] presumed to localize to the endoplasmic 
reticulum and Golgi apparatus [14]. Efforts to understand 
the contribution of E5 to HPV pathogenesis have shown 
that it induces anchorage-independent growth in murine 
fibroblasts and growth in low serum [15, 16], whilst 
demonstrating weak transforming activity in primary 
human keratinocytes [17]. Several studies have shown that 
E5 potentiates EGFR signalling, and modulation of this 
pathway is implicated in its transforming ability [12, 18]. 
Transgenic mouse models expressing HPV16 E5 in the 
epithelium display hyperplasia, resulting in spontaneous 
tumour formation [19]. These mice also display increased 
dysplastic disease in the cervical epithelium [20]. 
Importantly, the epithelial hyperplasia induced by E5 
is attenuated when the EGFR pathway is inhibited by 
expression of a dominant negative EGFR [19]. In cervical 
cancers HPV genomes are regularly integrated into host 
DNA, and this occurs such that the E5 gene is often lost. 
This suggests that E5 plays a critical role in the genesis 
of cervical cancer but less of a role in its progression or 
persistence.
Studies of E5 function in high-risk HPV16 [21] and 
HPV31 [22] life cycle models show that E5 function is 
likely not required by the virus in undifferentiated cells, but 
does play a role during the productive stages of infection 
in the differentiated epithelium. They highlight a need for 
E5 in regulating host cell cycle progression and aiding 
virus genome amplification. Despite these advances, the 
mechanisms by which E5 regulates these processes are 
unknown [23, 24]. Interestingly, neither study identified 
any differences in suprabasal differentiation in the absence 
of E5. These findings are disputed by more recent in vivo 
studies, highlighting a role for E5 in the deregulation of 
differentiation in the epithelia of the HPV16 transgenic 
mouse [19]. Subtle differences are also observed in the 
requirement for E5 between the two HPV types tested. 
These might relate to differences in experimental design, 
or the use of immortalized keratinocytes to study HPV16 
versus primary keratinocytes to test HPV31. Alternatively, 
they may relate to genuine type specific differences in the 
role of E5. Finally, no apparent role for EGFR signalling 
was identified in either model, which is distinct from 
evidence supporting manipulation of this pathway in 
cells expressing E5, or the requirement for EGFR in E5-
mediated transformation shown in the transgenic mouse 
model.
Given these disparities and the possibility of HPV 
type specific differences in E5 function, we examined 
the role of E5 in the HPV18 life cycle utilizing a primary 
human keratinocyte model system [25–27]. We confirm 
that loss of E5 function impacts on the productive stages 
of the virus life cycle and impairs maintenance of the 
cell cycle upon keratinocyte differentiation. We provide 
new evidence highlighting a role for E5 in impairing 
keratinocyte differentiation. At the biochemical level, 
E5 suppresses the KGFR pathway, whilst enhancing 
proliferative signalling. Use of small molecule inhibitors 
and expression of mutant signalling proteins affirms 
that keratinocyte differentiation requires an integrated 
signalling response with significant cross talk between 
pathways. In particular, attenuation of EGFR signalling 
impacted on all pathways studied. These data indicate that 
E5 subverts EGFR signalling as a unifying mechanism 
to alter proliferation and differentiation pathways in 
keratinocytes.
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RESULTS
Loss of E5 expression does not alter HPV18 
genome establishment in undifferentiated 
primary human keratinocytes
To study the role of E5 in the HPV18 life cycle, 
we generated a mutant HPV18 genome in which the E5 
open reading frame was disrupted by the introduction 
of a translation termination codon. This mutant, HPV18 
E5KO, contains a single nucleotide change at position 
3940, inserting a translational stop codon at position 2 in 
the E5 sequence. The mutation would not be expected to 
interfere with any of the splice sites recently identified in 
the HPV18 genome [23, 28]. Wild type (WT) and E5KO 
(KO) HPV18 genomes were transfected into low passage 
neonate normal human keratinocytes (NHK) obtained 
from two individual foreskin donors. Southern blotting 
of total genomic DNA isolated from undifferentiated 
monolayer cultures showed that the WT and E5KO viral 
genomes were established as extra-chromosomal episomes 
(Figure 1A). Whilst minor differences exist in absolute 
genome copy number per cell in each donor, no significant 
differences were observed between the WT (donor 1: 172 
and donor 2: 208) and E5KO (donor 1: 168 and donor 
2: 194) genome-containing cells. After serial passaging 
of the cell lines (average population doubling times: WT, 
34 hours; E5KO, 31 hours) the HPV18 episomes were 
maintained in the absence of E5 protein (data not shown). 
Whilst no antibody exists to detect E5, to ensure that the 
mutagenesis strategy did not adversely affect E6 and/or 
E7 expression, the levels of the two oncoproteins were 
assessed in lysates from cells cultured in high calcium 
media for over 72 hours (Figure 1B). Levels of both 
oncoproteins were highest in undifferentiated WT and 
E5KO cells and upon differentiation the levels of both 
proteins declined. Importantly, there was little variation 
of either oncoprotein between WT and E5KO cell lines 
under study.
E5 supports cell cycle re-entry of post-mitotic 
suprabasal keratinocytes
Given a lack of requirement for E5 function in the 
early stages of the HPV18 life cycle we investigated its role 
during the differentiation-dependent stage of the infectious 
cycle. At this stage, the virus is required to re-establish 
cell cycle progression in the post-mitotic suprabasal 
cells to stimulate unscheduled host cell DNA synthesis 
to provide an environment conducive to virus genome 
amplification. To investigate the effect of E5 function on 
host DNA replication, HPV18 genome-containing lines 
were stratified in organotypic raft cultures for 13 days 
and the thymidine analogue bromodeoxyuridine (BrdU) 
was incorporated over the final 16 hours before fixation. 
The percentages of BrdU-positive cells present in the raft 
cultures were then quantified. As expected, BrdU-positive 
cells were confined to the basal layer in NHK-derived 
rafts, whereas BrdU-positive nuclei were detected in both 
the basal and suprabasal compartments of WT and E5KO 
genome containing cells (Figure 1C). Quantification of the 
number of BrdU positive nuclei revealed no significant 
differences in BrdU staining in the basal layers in E5KO 
cells compared to WT (Figure 1C and 1D). In contrast, 
a statistically significant decrease in BrdU staining was 
observed in the suprabasal layers in the E5KO rafts, 
which was consistent between donors (Figure 1C and 1D). 
Despite the decrease in DNA synthesis observed in the 
E5KO rafts, this did not equate to gross morphological 
changes in the rafts as observed in haematoxylin and eosin 
stained sections (Figure 1C).
Recent observations suggest that HPV DNA 
amplification occurs in suprabasal cells that have entered 
a protracted G2 phase of the cell cycle [29]. Cells in G2 
are identified by cytoplasmic cyclin B1 expression; the 
cyclin-cdk complex is retained in the cytoplasm in an 
inactive form and must first be dephosphorylated prior 
to the nuclear translocation observed during mitosis. To 
determine if E5 function was necessary for progression of 
the viral genome-containing cells through to G2, cyclin 
B1 expression was assessed. Cytoplasmic cyclin B1 was 
restricted to the basal layer of NHK raft cultures (Figure 
2A). In the WT and E5KO cultures, cytoplasmic cyclin B1 
was detected in the basal and suprabasal layers (Figure 2A 
and 2B). Whilst levels of cyclin B1 positive stained cells 
in the basal layer did not differ, we observed a significant 
loss of cyclin B1 staining in the suprabasal layers of the 
E5KO rafts (Figure 2A and 2B).
These data were confirmed in cells differentiated 
in high calcium media for 72 hours. Cyclin B1 levels 
declined rapidly in differentiated NHK (Figure 2C: 
lanes 1-3). In accordance with observations from raft 
cultures cyclin B1 expression persisted in differentiating 
keratinocytes harbouring HPV18 WT and E5KO cells 
(Figure 2C lanes 4-6, 7-9). However, at 72 hours the level 
of cyclin B1 in the E5KO cells was significantly reduced 
compared to WT (Figure 2C; compare lanes 6 and 9) 
(Quantification in Figure 2D). Taken together, these data 
suggest that E5 contributes to the maintenance of cell 
cycle activity in suprabasal cells.
E5 is not necessary for HPV18 genome 
amplification or late viral protein expression in 
differentiating keratinocytes
Given that our data indicated a decrease in the 
ability of cells containing the E5KO genomes to retain 
proliferative potential once exposed to differentiation 
stimuli, we examined viral genome amplification by 
chromogenic in situ hybridisation (CISH) using a HPV 
specific probe on raft sections. As shown in Figure 
3A, intensely stained nuclei, corresponding to cells 
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Figure 1: HPV18 E5 contributes towards unscheduled host cell DNA synthesis upon keratinocyte differentiation. (A) 
Southern analysis of equal amounts of total DNA extracted from NHK transfected with wild-type (WT) or mutant (E5KO) genomes in two 
different donors. DNA was digested with DpnI (digests input DNA) together with BglII which does not digest HPV18 DNA or EcoRI which 
linearizes HPV18 genomes. (B) Detection of E6 and E7 proteins in equal amounts of Triton-X100 detergent soluble protein lysates prepared 
from cells differentiated in high-calcium monolayer cultures. Levels of GAPDH were used as a loading control. Densitometry analysis of 
protein bands was performed using ImageJ software. (C) Organotypic rafts were incubated with BrdU to identify nuclei positive for cellular 
DNA synthesis. BrdU positive cells were visualised with an anti-BrdU antibody (red) and nuclei visualised with DAPI (blue). White dotted 
lines indicate the basal cell layer. Red scale bar represents 20 μm. Organotypic raft cultures were also stained with haematoxylin and 
eosin to observe the gross morphology of the epithelium. (D) Graphs showing the percentage of BrdU positive nuclei in basal and lower 
suprabasal and upper suprabasal layers. The data, shown as a mean with standard deviation, were derived from 15 fields of view of each 
raft and from 3 independent experiments from two donors cell lines. Significance as determined by Student’s t-test is shown as ** = p<0.01, 
*** = p<0.001.
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undergoing viral DNA amplification, were found in 
cells of the upper suprabasal layers of the rafts carrying 
WT and E5KO genomes. Quantification of the data did 
not show a significant difference in the number of cells 
undergoing viral genome amplification in the absence of 
E5 (Figure 3A). These results indicate that whilst loss of 
E5 impacts on host suprabasal DNA synthesis, it does not 
make a significant contribution towards virus genome 
amplification.
Expression of the virus capsid proteins and the 
E4 protein occurs in the more differentiated cells of the 
epithelium. To determine if loss of E5 affected these 
hallmarks of the productive life cycle, rafts were stained 
with antibodies that recognise E4, an HPV protein that is 
up-regulated at the onset of viral genome amplification 
(Figure 3B), and the major capsid protein L1 (Figure 3C). 
In rafts of cells containing the WT genomes staining of 
E4 and L1 was observed in the upper suprabasal layers. 
No significant differences in the staining patterns were 
observed between WT and E5KO cells. Taken together, 
these data indicate that HPV18 E5 is not required for the 
expression of late viral proteins and concurs with previous 
findings from the HPV16 life cycle model lacking E5 
expression [21].
HPV18 E5 enhances EGFR expression in 
primary human keratinocytes
EGFR signalling is a major driver of proliferation in 
the basal compartment of the epithelium [6]. It regulates 
the activity of downstream components such as ERK/
MAPK, which are essential for G2/M progression in 
Figure 2: HPV18 E5 deregulates cell cycle progression in differentiated cells. (A) Organotypic rafts stained for cyclin B1 
(green) and nuclei stained with DAPI (blue), white dotted lines indicate the basal cell layer. Red scale bar represents 20 μm. (B) Graphs 
showing the percentage of cyclin B1 positive nuclei in basal and suprabasal layers. The data, shown as a mean with standard deviation, 
were derived from 15 fields of view of each raft and from 3 independent experiments from two donor cell lines. Significance as determined 
by Student’s t-test is shown as *** = p<0.001. (C) Lysates of NHK, WT and E5KO cells subjected to high calcium differentiation were 
analysed for cyclin B1 expression by immunoblotting. GAPDH served as a loading control. (D) Graph showing densitometry analysis of 
cyclin B1 expression at 72 hours for two donors. The data is shown as a mean and standard deviation from three independent experiments. 
Significance as determined by Student’s t-test is shown as * = p<0.05 and **** = p<0.0001.
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primary keratinocytes [5]. Expression of isolated E5 
has been shown to augment EGFR expression and 
autophosphorylation, and to enhance mitogenic signalling 
[30]. To determine if the effects of E5 on the cell cycle 
progression of post mitotic keratinocytes was linked to 
an effect on EGFR signalling during the differentiation 
dependent life cycle, NHK and HPV18 genome-
containing keratinocytes were stratified in raft culture and 
levels of total EGFR detected by immunofluorescence 
staining. EGFR expression was restricted to the basal cells 
in normal human keratinocytes (Figure 4A). In contrast, 
WT genome containing rafts exhibited a marked increase 
in plasma membrane localised EGFR expression in the 
basal and suprabasal layers (Figure 4A). E5KO rafts also 
displayed increased plasma membrane localised EGFR 
expression in the basal compartment, however, suprabasal 
EGFR expression was reduced compared to WT rafts 
(Figure 4A). WT and E5KO rafts were digitally scanned 
from basal layer to the top and analysed by cross-sectional 
imaging analysis (Figure 4B). No obvious difference was 
observed in the EGFR expression profile in the lower 
epithelial layers; however, this analysis clearly highlighted 
the loss of EGFR expression in the upper suprabasal layers 
of E5KO rafts (Figure 4B; highlighted by an arrow).
EGFR levels were also determined by western 
blot of lysates from keratinocytes grown in high calcium 
media. In monolayer culture, NHK cells expressed low 
levels of EGFR, detectable only after longer exposure 
of the blot (Figure 4C; lanes 1-3). In contrast, EGFR 
expression was substantially increased in undifferentiated 
keratinocytes harbouring either WT or E5KO genomes 
compared to NHK (Figure 4C; compare lanes 1, 4 and 
7). Upon differentiation, the level of EGFR protein 
declined moderately but was still detectable at 72 h in WT 
containing keratinocytes (Figure 4C; lanes 4-6). In the 
absence of E5, EGFR expression declined rapidly and was 
90% lower than in WT cells at 72 h (Figure 4C; compare 
lanes 6 and 9 – p<0.0007). These data demonstrate that 
Figure 3: HPV18 E5 function is not necessary for genome amplification and late protein expression in differentiating 
keratinocytes. (A) Organotypic raft cultures were probed with a biotin-conjugated HPV DNA specific for the high-risk HPV types to 
visualise genome amplification. Arrows indicate examples of CISH positive nuclei. Graph represents the mean (± standard deviation) of 
CISH positive nuclei per field of view (15 fields of view of each raft) for two separate donors. (B and C) Organotypic rafts stained for E4 
(red) and L1 (green), nuclei were visualised with DAPI (blue). White dotted lines indicate the basal cell layer. Red scale bar represents 20 
μm. Images are representative of staining from two donors and three independent experiments.
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E5 maintains the increase in EGFR expression observed 
in suprabasal cells, but is not required for increased EGFR 
in the basal layer of the epithelium.
Active EGFR is needed for cyclin B1 expression 
in differentiating keratinocytes
Next we studied the contribution of EGFR-ERK 
MAPK signalling to the cyclin B1 expression observed 
in differentiated HPV18 containing keratinocytes 
(Figure 5A). WT cells were transfected with a pool of 
commercially available, validated siRNA to deplete EGFR 
expression or a scrambled control, and cells cultured in 
high calcium media for 48 hours to induce differentiation. 
As expected, WT cells transfected with the scrambled 
control retained EGFR expression upon differentiation 
(Figure 5B; compare lanes 1 and 2). In contrast, 
transfection of the pool of EGFR specific siRNA resulted 
in a 50% reduction in EGFR levels in the differentiated 
cells (Figure 5B; compare lanes 2 and 3). The reduction in 
EGFR protein expression correlated with a 40% decrease 
in ERK1/2 phosphorylation, indicating that the signalling 
pathway was impaired. Importantly, a decrease in cyclin 
B1 expression to similar levels as in the E5KO cells 
was observed (Figure 5B; compare lanes 3 and 5). To 
investigate whether an active EGFR kinase was necessary 
for the increased cyclin B1 expression, keratinocytes 
harbouring WT genomes were grown in high calcium 
media for 48 hours in the presence of 2 μM of a specific 
and highly potent small molecule inhibitor targeting the 
intracellular EGFR kinase domain (PD153035 - [31]) 
(Figure 5C). Whereas the untreated WT cells retained 
cyclin B1 upon differentiation, cells treated with the 
EGFR inhibitor had reduced cyclin B1 expression similar 
to levels observed in the E5KO cells (Figure 5C; compare 
lanes 2 and 3 plus 3 and 5). The reduction in cyclin B1 
expression correlated to reduced ERK1/2 phosphorylation, 
demonstrating that EGFR signalling was successfully 
inhibited (Figure 5C; compare lanes 2 and 3).
Similar results were observed with a specific small 
molecule inhibitor of Mek1/2 (UO126 – 20 μM - [32]), 
which inhibits activation of the ERK1/2 MAPK cascade 
(Figure 5D). These results indicate that activation of 
EGFR is necessary for the differentiation-dependent 
cyclin B1 expression in HPV18 genome containing cells. 
Notably, they also demonstrate that the blockade of this 
Figure 4: HPV18 E5 maintains EGFR expression in differentiating keratinocytes. (A) Organotypic rafts stained for EGFR 
(green), with nuclei stained with DAPI (blue). White dotted lines indicate the basal cell layer. Red scale bar represents 20 μm. Images are 
representative of staining from two donors. (B) Histogram analysis of the staining intensity from WT and E5KO rafts. Data was derived 
from 5 fields of view from three independent experiments and two donors. (C) Lysates of keratinocytes differentiated in high calcium media 
analysed for total EGFR expression by immunoblotting. GAPDH served as a loading control. Western blots are representative of three 
independent experiments in two donor lines.
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signalling pathway in cells harbouring the WT genomes 
lowers cyclin B1 levels to those observed in cells that lack 
E5 expression.
HPV18 E5 reduces keratinocyte differentiation
Active EGFR is associated with a failure of 
differentiation in the epithelium. We hypothesized that 
enhanced EGFR expression might result in delayed 
keratinocyte differentiation. A defect in involucrin 
expression was observed in the E5KO cells by western 
blot of lysates from cells cultured in high calcium 
medium (Figure 6). In NHK and E5KO cells the levels of 
involucrin had risen markedly by 48 h growth in calcium, 
whereas in the WT cells levels of involucrin were 6-fold 
lower at 48h (p<0.02) and high levels of expression were 
achieved only after 72 h growth (Figure 6; compare lanes 
2, 5 and 8). Similarly, levels of another differentiation 
marker – cytokeratin 1 – were perturbed in WT versus 
E5KO containing cells (Figure 6). These data indicate 
that E5 contributes to the HPV18 mediated suppression of 
epithelial differentiation.
Negative regulation of the keratinocyte 
growth factor receptor (KGFR/FGFR2IIIb) by 
HPV18 E5
To understand the mechanisms by which E5 
regulates keratinocyte differentiation, we focused on the 
KGFR/FGFR2IIIb pathway. KGFR is a splice variant 
of the fibroblast growth factor receptor 2 (FGFR2IIIb) 
exclusively expressed in epithelial cells [33]. Reports have 
linked KGFR to skin homeostasis and as a regulator of the 
balance between proliferation and differentiation [9]. Mice 
lacking KGFR expression in skin epithelia display aberrant 
keratinocyte proliferation, impaired differentiation and are 
prone to the development of papilloma-like lesions [9]. 
First, levels of KGFR protein expression were examined 
by immunofluorescence staining in raft cultures (Figure 
7A and 7B). As expected, KGFR expression was restricted 
to the suprabasal layers of the epithelium (Figure 7A and 
7B). In NHK cells KGFR expression was only detected 
in the mid and upper suprabasal layers of the epithelium 
(Figure 7A). Overall levels of KGFR protein were reduced 
in WT containing cells, whilst the E5KO rafts showed a 
KGFR expression profile more similar to that observed 
in the NHK cells, with abundant KGFR seen in the mid 
and upper suprabasal layers (Figure 7A and 7B). HPV16 
E5 has been suggested to impair KGFR transcription 
when overexpressed in HaCaT cells [34]. We were able 
to confirm that levels of KGFR mRNA were significantly 
lower in calcium differentiated WT compared to E5KO 
containing cells (Figure 7C).
EGFR signalling suppresses KGFR expression
The EGFR pathway has been proposed to function 
as an inhibitor of KGFR expression [6, 35]. We tested 
whether KGFR expression could be repressed through 
EGFR signalling by treating cells harbouring WT genomes 
with the EGFR kinase inhibitor PD153035 over a 48 hour 
time course of differentiation with high calcium (Figure 
7D). Cells were then lysed and assayed by western blot for 
KGFR activation. Due to inadequate antibody reagents, 
the phosphorylated form of FRS2α, a docking protein 
phosphorylated by the active form of KGFR, was used 
as a surrogate for active KGFR expression (Figure 7D) 
[33]. Levels of P-FRS2α were higher in differentiated 
E5KO compared to WT lysates (Figure 7E; compare lanes 
2 and 5). Importantly, chemical inhibition of EGFR kinase 
Figure 5: HPV18 requires EGFR activation to maintain cyclin B1 expression in differentiating cells. (A) Schematic 
showing the EGFR/ERK signalling pathway and the targets of the siRNA and inhibitors used in this study. Mock treatedkeratinocytes were 
differentiated in high calcium media and lysed after 48 hours. In parallel, keratinocytes were treated with (B) scramble or EGFR specific 
siRNA, (C) an EGFR kinase inhibitor (2 μM PD153035), or (D) a Mek1/2 kinase inhibitor (20 μM UO126) during differentiation. All 
samples were analysed for cyclin B1 and phosphorylated ERK1/2 expression. GAPDH served as a loading control. Representative blots are 
shown from at least three independent biological repeats from two donor lines.
Oncotarget103589www.impactjournals.com/oncotarget
Figure 6: HPV18 E5 impairs keratinocyte 
differentiation. Lysates of NHK, WT and E5KO keratinocytes 
subjected to high calcium differentiation were analysed for 
involucrin and cytokeratin 1 (K1) expression. GAPDH served 
as a loading control. Western blots are representative of three 
independent experiments in two donor lines.
activity (Figure 7D; compare lanes 2 and 3) resulted in 
an increase in the phosphorylated form of FRS2α, which 
correlates with active KGFR signalling.
KGFR signalling is impaired in cells harbouring 
HPV18 genomes
AKT is a master serine/threonine kinase, which 
acts as a major downstream effector of KGFR during 
keratinocyte differentiation. Upon KGFR mediated 
activation of phosphatidylinositol 3-kinase (PI3-kinase), 
and the subsequent generation of phosphatidylinositol 
3,4,5-trisphosphate, AKT is recruited to the plasma 
membrane, where it is phosphorylated and activated 
[36]. AKT phosphorylates a number of substrates in 
the cytoplasm and nucleus associated with keratinocyte 
differentiation and survival e.g. GSK3β (Figure 8A) 
[37, 38]. To understand the implications of the loss of 
KGFR expression on down-stream signalling pathways, 
we examined the expression and post-translational 
modification of AKT in our HPV genome-containing 
cell lines upon differentiation in high calcium medium. 
The levels of total AKT diminished slightly upon 
differentiation, although they remained higher in HPV18 
containing cells compared to NHK controls and the loss 
of E5 expression did not impact on the increase in AKT 
(Figure 8B; compare lanes 1, 3 and 7). Whilst the level 
of total AKT protein decreased upon differentiation, 
there was a differentiation-dependent increase in 
Ser473 AKT phosphorylation in NHK cells (Figure 8B; 
compare lanes 1 with 2 and 3). In contrast, the level of 
phosphorylated Ser473 AKT was substantially reduced 
in the WT containing cells, both in undifferentiated and 
in differentiated cells (Figure 8B; compare lanes 1 and 4, 
3 and 6). The loss of E5 protein reinstated the temporal 
pattern of differentiation-dependent AKT phosphorylation 
(14 fold increase in P-AKT in the E5KO compared to WT 
at 72h – p<0.02), although the level of phosphorylation 
was lower than in the NHK cells (Figure 8B: compare 
lanes 1, 4 and 7 and 3, 6 and 9).
A similar loss in the differentiation-dependent 
increase in GSK3β phosphorylation was observed in 
WT genome-containing cells (Figure 8B; compare 
lanes 1-3 and 4-6). Again, E5KO cells recapitulated the 
pattern of GSK3β phosphorylation observed in NHK 
cells but to lower levels (Figure 8B; compare lanes 1-3 
with 7-9). Together these data indicate that HPV18 E5 
reduces differentiation-dependent AKT activation in 
keratinocytes.
Pharmacological blockade of KGFR 
compensates for the loss of E5 and delays 
keratinocyte differentiation
To investigate whether the failure of E5KO cells 
to impair differentiation was due to an inability to down-
regulate KGFR signalling, we determined whether 
pharmacological inhibition of the KGFR pathway might 
compensate for loss of E5. To inhibit KGFR kinase 
activity, E5KO cells were differentiated in the presence 
of PD173074 (30 nM), a potent small molecule inhibitor 
targeting FGFR2 kinases (Figure 9A) [39]. We first 
confirmed the effects of PD173074 by assessing the 
phosphorylation status of the adaptor protein FRS2α. 
As expected, levels of FRS2α phosphorylation were 
greater in the E5KO cells upon differentiation compared 
to WT (Figure 9B, compare lanes 2 and 4), indicating 
increased KGFR activity. The addition of PD173074 
reduced the levels of FRS2α phosphorylation in the E5KO 
cells, and this effect correlated with a decrease in AKT 
phosphorylation and reduced expression of cytokeratin 1 
(Figure 9B).
We were intrigued to test whether pharmacological 
blockade of KGFR might also increase cyclin B1 
expression in the E5KO cells. Treatment with the KGFR 
inhibitor had no impact on cyclin B1 expression in the 
E5KO cells (Figure 9B). This indicates that the E5 mediated 
increase in cyclin B1 expression is either upstream of 
KGFR repression or within a separate signalling network. 
We conclude that blockade of KGFR in cells harbouring 
HPV18 E5KO genomes rescues the differentiation 
phenotype associated with the absence of E5, but cannot 
prevent the reduction of cyclin B1 expression.
AKT is essential for the E5-mediated reduction 
in keratinocyte differentiation
Our data indicates that suppression of KGFR by E5 
was necessary to reduce keratinocyte differentiation, and 
raised the possibility that the regulation of downstream 
components of KGFR signalling might be critical for 
keratinocyte differentiation and the productive virus life 
cycle. One such effector is AKT, which plays a functional 
role in the construction of the suprabasal layers [38]. We 
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sought to determine the contribution of AKT inhibition by 
E5 to keratinocyte differentiation (Figure 10A). We asked 
whether a myristoylated form of AKT1 – the predominant 
isoform of AKT in human keratinocytes [38] – that is 
targeted to the membrane independently of PI3-kinase 
activity could overcome the delay in early differentiation 
exhibited in keratinocytes harbouring HPV18 genomes. 
WT genome containing cells were transduced with a 
retrovirus encoding AKT1 containing an amino terminal 
HA epitope tag engineered to contain the myristoylation 
signal sequence from the c-Src tyrosine kinase [40], and 
subsequently cultured in high calcium containing media 
for 48 hours. Analysis of the protein lysates by western 
blot confirmed the low levels of the differentiation marker 
cytokeratin 1 in WT cells compared to those lacking 
E5 (Figure 10B; compare lanes 2 and 5). In contrast, 
cells expressing constitutively active AKT1 overcame 
the HPV18 mediated block and expressed levels of 
cytokeratin 1 similar to the E5KO cell line (Figure 10B; 
compare lanes 2 and 3). Western blotting with an antibody 
recognizing the HA epitope confirmed expression of the 
exogenous AKT1 in the appropriate sample.
If AKT is a critical host target for E5 function, then 
we anticipated that the introduction of a dominant negative 
form of this protein might compensate for the lack of E5 
and delay keratinocyte differentiation (Figure 10A). To 
test this, E5KO cells were transduced with a retrovirus 
encoding a kinase inactive version of the myristoylated 
AKT1 protein and differentiated for 48 hours in the 
presence of high calcium. Western blotting with an anti-
Figure 7: HPV18 E5 inhibits the KGFR signalling pathway. (A) Organotypic raft cultures stained for KGFR expression (red) and 
nuclei stained with DAPI (blue). White dotted lines indicate the basal cell layer. Red scale bar represents 20 μm. Images are representative 
of staining from two donors. (B) Histogram analysis of the staining intensity from WT and E5KO rafts. Data was derived from 5 fields of 
view from three independent experiments, from two donors. (C) Graph showing relative KGFR mRNA expression in differentiated WT and 
E5KO keratinocytes after 96 hours incubation in high calcium media. Results were corrected for expression of an U6 loading control. The 
data is shown as a mean and standard deviation from three independent biological repeats from two donors. Significance as determined by 
Student’s t-test is shown as ** = p<0.01. (D) Schematic showing the interplay between the EGFR/KGFR signalling pathway and the target 
of the inhibitor used in this study. (E) Mock-treated keratinocytes were differentiated in high calcium media and lysed after 48 hours. In 
parallel, keratinocytes were treated with an EGFR kinase inhibitor (2 μM PD153035), during differentiation. All samples were analysed 
for phosphorylated FRS2α expression. GAPDH served as a loading control. Representative blots are shown from at least three independent 
biological repeats from two donor lines.
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HA antibody confirmed exogenous AKT1 expression 
(Figure 10C). As predicted, the differentiation-induced 
increase in cytokeratin 1 expression associated with the 
E5KO cells was significantly reduced in cells expressing 
the dominant negative AKT1, almost to levels observed in 
cells harbouring the WT genomes (Figure 10C; compare 
lanes 4 and 5). Thus, E5 function to delay keratinocyte 
differentiation correlates with a deregulation of AKT 
activity.
DISCUSSION
This study provides a comprehensive analysis 
of E5 function during productive infection by HPV18; 
the second most prevalent high-risk type. We found 
little impact of the loss of E5 on the HPV life cycle in 
undifferentiated cells, in agreement with previous studies 
in keratinocyte-based model systems of the HPV16 and 
HPV31 viruses [21, 22]. E5KO genomes efficiently 
established episomes and the genome-containing 
cells showed no growth disadvantage under these 
undifferentiated conditions. One possible explanation 
for these findings might lie in the polycistronic nature 
of HPV gene expression. Whilst recent transcript 
mapping studies show that E5 is present on abundant 
transcripts, it is often last in the polycistronic message 
and as such it may be inefficiently expressed in 
undifferentiated conditions [28]. Unfortunately, the 
absence of an effective E5 antibody makes this difficult 
to test. Alternatively, it is possible that in basal cells an 
additional early protein (e.g. E6 or E7) compensates for 
the loss of E5.
This study clearly demonstrates that E5 is required 
to effectively drive cell cycle re-entry in suprabasal cells, 
as judged by repression of both on-going host cell DNA 
synthesis and elevated cytoplasmic cyclin B1 expression 
in the suprabasal regions of E5KO rafts. Given that viral 
DNA amplification is thought to be initiated in cells with 
cytoplasmic cyclin B1 [29], we studied whether E5 might 
contribute to this process and observed no reduction in 
the number of cells supporting virus genome amplification 
upon differentiation. In fact, there was no significant 
impact of E5 loss on HPV18 late gene expression, as 
tested by immunostaining of raft cultures for E4 and L1 
proteins. Thus, our data fit the recently described model, 
[23], whereby high levels of viral genome amplification 
are necessary for late protein expression. Our findings are 
in agreement with the HPV16 E5 knockout model, which 
also saw no decrease in late protein expression [21], but 
are in disagreement with Fehrmann and colleagues who 
observed a significant decrease in E4 expression in HPV31 
E5KO cells [22]. Whether these differences are due to 
alternative experimental techniques or are a genuine type-
specific difference between E5 functions awaits further 
study. With regards to the latter, HPV18 is predominantly 
associated with adenocarcinomas of the cervix, whereas 
HPV16 and HPV31 have a strong association with 
squamous carcinomas; these differences in pathogenesis 
may indicate differences in life cycle biology. Indeed, 
it has recently been shown that E4 function is markedly 
different between HPV16 and HPV18 [41]. Thus, our data 
suggest that E5 is required to modulate the host cell milieu 
to generate cell cycle progression at particular stages of 
the productive HPV18 life cycle, but perhaps its loss 
can be compensated for by other viral protein functions, 
including E7, E6 or E4.
Whilst the requirement for E5 in cell cycle 
progression was observed in the previous studies [21, 22], 
neither study was able to provide a definitive link between 
cell cycle progression and EGFR signalling. This was 
surprising given the body of literature demonstrating 
a link between E5 expression and EGFR activation 
coupled with the understanding that EGFR-ERK MAPK 
Figure 8: HPV18 E5 inhibits downstream targets of 
the KGFR signalling pathway. (A) Schematic showing 
the KGFR downstream signalling pathway including the KGFR 
substrate FRS2a and downstream kinases AKT and GSK3β. (B) 
Lysates of NHK, WT and E5KO keratinocytes subjected to high 
calcium differentiation were analysed for p-AKT, total AKT 
and p-GSK3β. GAPDH served as a loading control. Western 
blots are representative of three independent experiments in two 
donor lines
Oncotarget103592www.impactjournals.com/oncotarget
Figure 9: Pharmacological inhibition of KGFR activity compensates for loss of E5 and impairs keratinocyte 
differentiation. (A) Schematic showing the KGFR signalling pathway and target of the pharmacological inhibitor. (B) Control (vehicle 
only) keratinocytes were differentiated in high calcium media and lysed after 48 hours. Parallel cultures of E5KO keratinocytes were treated 
with 30 nM of a KGFR kinase inhibitor (PD173074). Lysates were analysed for the phosphorylated forms of FRS2α, AKT, GSK3α/β, 
cytokeratin 1 (K1) and cyclin B1 by immunoblot.
signalling is a major driver of cyclin B1 expression 
in keratinocytes [5, 6]. We observed enhanced EGFR 
expression and activity in differentiated keratinocytes 
containing HPV18 genomes compared to parental control 
cells. Absence of E5 correlated with reduced suprabasal 
EGFR expression but had no impact on EGFR expressed 
in the basal compartment. These data are consistent with 
the notion that E5 is not expressed and/or required in 
basal cells and that in these cells another HPV encoded 
protein increases EGFR expression. Through the use of 
siRNA depletion we were able to demonstrate that the 
increased EGFR expression is necessary for cyclin B1 
expression in differentiating keratinocytes. Moreover, 
small molecule inhibitors inactivating the EGFR kinase 
domain demonstrate that an active EGFR is required for 
this process. A prevailing model for E5-mediated EGFR 
expression suggests a mechanism linked with endosome 
deacidification or modulation of intracellular endosomal 
trafficking, whereby activated EGFR are re-routed from 
a degradative pathway into recycling endosomes, from 
which they are trafficked back to the plasma membrane. 
This might be accomplished by impaired endosome 
acidification resulting from either interaction with the 
vacuolar ATPase [42], modulation of endosome maturation 
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[43] or involve the recently described viroporin activity of 
E5 [13].
Proliferative signalling is also known to suppress 
expression of proteins that positively regulate epithelial 
differentiation. We discerned a significant defect in 
differentiation marker expression in cells harbouring the 
HPV18 genomes. Despite the increase in proliferative 
potential in cells harbouring HPV16 and HPV31 genomes, 
no apparent differences were observed in differentiation 
marker expression in the absence of E5 expression 
[21, 22]. These findings do not correspond with the 
disturbances in epithelial differentiation observed in the 
Figure 10: AKT is essential for the modulation of keratinocyte differentiation by HPV18. (A) Schematic showing the KGFR 
signalling pathway and the effects of the dominant active (DA) and negative (DN) AKT. HPV18 genome containing keratinocytes were 
infected with empty retrovirus, or with retroviruses encoding DA AKT (B) or DN AKT (C). Cells were differentiated in high calcium media 
for 48 hours prior to lysis and analysed for expression of cytokeratin 1 (K1) to assess differentiation. Expression of the exogenous AKT was 
confirmed using an antibody against the HA epitope and GAPDH served as a loading control.
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HPV16 E5 transgenic mouse model [19]. It is unclear 
why the HPV18 life cycle model shows such an overt 
differentiation phenotype in comparison to comparable 
studies of HPV16 and 31. One explanation might lie 
in the level of proliferative signalling controlled by 
E5 in HPV18 containing cells. Since EGFR signalling 
suppresses differentiation it is possible that HPV18 E5 is 
more effective at suppressing these pathways than E5 from 
other high-risk types studied to date.
Since the KGFR pathway is a known regulator 
of the early stages in suprabasal differentiation, we 
tested whether manipulation of KGFR might contribute 
to the defect in differentiation observed in primary 
keratinocytes harbouring the HPV18 genome. In support 
of this, the KGFR pathway is inhibited in HaCaT cells 
constitutively expressing isolated HPV16 E5 [44]. KGFR 
signalling was impaired in cells harbouring the WT 
HPV18 genomes. In particular, we studied the KGFR 
effector AKT, a serine/threonine kinase that regulates 
a number of events in suprabasal cells. Levels of AKT 
phosphorylation and kinase activity were suppressed in 
cells harbouring HPV18. We were able to demonstrate 
the importance of the KGFR-AKT pathway for 
differentiation using a combination of small molecule 
inhibitors and retrovirus encoded dominant active and 
negative AKT proteins. Notably, treatment of E5KO 
cells with a KGFR kinase inhibitor or over-expression of 
a dominant negative AKT protein compensated for the 
loss of E5 during differentiation and exhibited a similar 
WT HPV18 differentiation marker expression profile. 
Figure 11: Schematic model depicting the proposed role of EGFR signalling in the E5-mediated manipulation of 
proliferation and differentiation pathways during the virus life cycle. E5 expression results in enhanced EGFR surface 
expression and activation, through a process that might require endosome recycling (1). This increases ERK/MAPK activity (2), resulting 
in activation of substrates, which include cell cycle associated proteins e.g. cyclin B (3). EGFR can suppress keratinocyte differentiation, 
by inhibiting a number of targets including the KGFR pathway. KGFR transcription is suppressed in E5 expressing cells (4) and KGFR 
signalling is markedly reduced (5). As a consequence, targets of KGFR including Akt are suppressed, culminating in loss of expression of 
a number of spinous associated differentiation markers e.g. cytokeratin 1 (K1) (6). As a result keratinocyte differentiation is impaired in 
cells expressing E5.
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In addition, overexpression of a dominant active AKT 
protein in cells harbouring WT viral genomes prevented 
the virus-associated delay in differentiation. Importantly, 
E5KO cells retain WT levels of E6 and E7 expression, 
which have been previously shown to potently suppress 
keratinocyte differentiation [24, 26, 46–51]. These data 
imply that AKT is a critical regulatory protein in the 
keratinocyte differentiation program. It will be of great 
interest to identify the targets of AKT that function to 
regulate differentiation in the context of HPV infection. 
One candidate is GSK3β, the phosphorylation of which is 
decreased in cells harbouring WT genomes. Interestingly, 
it has recently been shown that GSK3 β was more active 
in cells containing HPV31 [45]. Since phosphorylation 
of GSK3 β by AKT serves to inhibit the function of this 
protein our data corroborates these findings and implies 
that targeting of the AKT-GSK3β axis is a common feature 
between the high-risk viruses HPV18 and HPV31.
A number of HPV early protein knockout models 
have been used to great effect to dissect the apparent 
contribution made by each protein to the productive life 
cycle. A major observation from these studies is the level 
of redundancy of function, in particular between the three 
oncogenes. For example, loss of E7 impacts upon S-phase 
progression in suprabasal cells and loss of both E6 and 
E7 expression correlates with a dysfunctional delay to 
keratinocyte differentiation. We demonstrate that E5 
also targets these processes. We do not believe that our 
observations are due to any disturbance in E6 and/or E7 
expression in our E5 knockout model for three reasons. 
Firstly, no significant difference was observed in E6 and 
E7 expression between the WT and E5KO cells. Secondly, 
several of our findings have been noted using isolated 
E5 expression, including S-phase progression [52], 
EGFR hyperactivation [13] and suppression of KGFR 
transcription [34, 53]. Finally, the E5KO phenotype is 
subtler than either the E6 or E7 knockout phenotypes. For 
example, we observe no impact on genome maintenance, 
seen in the absence of E6 and despite a significant 
reduction in suprabasal DNA synthesis we see no effect on 
viral DNA amplification or late protein expression, both 
of which are abrogated in the absence of E7. Given the 
temporal nature of HPV protein expression it is possible 
that specific early proteins target similar pathways at 
distinct stages during epidermal differentiation. This 
would explain why little impact is seen in the basal 
cells of the E5KO keratinocyte based models. It is also 
possible that early proteins fulfil distinct roles in each 
papillomavirus type, and that each HPV type might 
modulate similar pathways using distinct early proteins 
targeting divergent host proteins. Large-scale proteomic 
screens of early protein binding partners from a range of 
HPV types may aid in addressing these possibilities [54].
This study demonstrates an unanticipated role for 
E5 in the HPV18 life cycle and identifies key epithelial 
pathways manipulated by this enigmatic oncoprotein. We 
show a unifying role for EGFR signalling in E5 function 
both as an enhancer of cell cycle progression and a 
repressor of epithelial differentiation (Figure 11). Given 
the importance of EGFR activation for E5 function it will 
be essential in the future to determine how E5 activates 
the EGFR and whether the importance of EGFR signalling 
is a shared feature of other HPV E5 proteins. Future 
studies should also focus on understanding the molecular 
interplay between the EGFR and KGFR pathways in HPV 
containing keratinocytes. Finally, it has been reported that 
E5 contributes to the immune evasion strategy of HPV by 
interfering with host MHC proteins in keratinocytes. Our 
model system provides an ideal opportunity to study this 
additional role during the productive HPV18 life cycle.
MATERIALS AND METHODS
Small molecule inhibitors
The quinazolone PD153035 is a specific and highly 
potent inhibitor of the EGFR kinase domain [31]. It was 
added to cells at a final concentration of 1 μM. UO126 
is a selective Mek1/2 inhibitor, and is used to inhibit 
activation of ERK1/2 [32]. It was added to cells at a final 
concentration of 20 μM. PD173074 was used to inhibit 
the kinase domain of the FGFR kinase member KGFR 
[39] and added to cells at a final concentration of 30 nM. 
PD153035, UO126 and PD173074 were purchased from 
Calbiochem.
Generation of E5 knockout-HPV18 pGEMII
pGEMII plasmid containing the complete HPV18 
genome (accession number: NC 001357) was a gift from 
F. Stubenrauch (University of Tübingen, Germany). 
A translation termination codon (TTA>TAA) was 
engineered immediately after the E5 start codon by site 
directed mutagenesis to include a translation termination 
codon (TTA>TAA) immediately after the E5 start 
codon using mutagenic primers FwdE5stopmutant and 
RevE5stopmutant (Supplementary Table 1). Briefly, 
10 ng of DNA was cycled 20 times with 240 ng of 
each mutagenic primer in a 50 μl reaction containing 
1x KOD PCR buffer, 0.3 mM of each dNTP and 1 U 
Thermococcus kodakaraenis KOD polymerase (Roche). 
Stbl2 cells (Invitrogen) were transformed with DpnI-
digested PCR product and used to amplify the plasmid 
DNA. Sequencing using GATC Biotech Ltd services 
was used to sequence the entire HPV18 genome to 
confirm mutagenesis of E5 and verify that no additional 
nucleotide changes had been generated during the 
mutagenesis protocol (primer sequences can be found in 
Supplementary Table 1).
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Cell transfection
The transfection of primary human foreskin 
keratinocytes (NHK) isolated from neonate foreskin 
tissues (ethical approval no. 06/Q1702/45 for the 
collection and use of neonate foreskin tissue) was 
performed in S. Roberts’ laboratory as described 
previously [26, 55]. To account for donor-specific 
effects, cell lines harbouring the HPV18 genomes were 
generated in NHK isolated from two donors. Briefly, 
plasmids containing the wild type (WT) and E5 knock-out 
(E5KO) were digested with EcoRI to release the genome, 
which was then re-circularised with T4 DNA ligase. The 
genomes were co-transfected with a plasmid encoding 
resistance to neomycin (pcDNA3.1, Invitrogen) into low 
passage NHK in serum free medium (Invitrogen). The 
cells were harvested 1 day later and seeded onto a layer 
of γ-irradiated J2-3T3 fibroblasts and selected with G418 
antibiotic in complete E medium containing 5% foetal 
calf serum (FCS, Lonza) and 5 ng/mL epidermal growth 
factor (BD BioSciences) for 8 days. Cell colonies that 
emerged were pooled and expanded on γ-irradiated J2-3T3 
fibroblasts in complete E medium.
siRNA transfection
A pool of 4 siRNA against EGFR (Targeting 
different regions of the mRNA) (Qiagen catalogue number 
GS1956) were transfected into HPV18 containing primary 
keratinocytes using lipofectamine 2000 transfection 
reagent (Life technologies) and incubated for 24 hours. 
The cells were then grown in serum free keratinocyte 
media containing 1.8mM CaCl2 for a further 48 hours.
Organotypic raft cultures
Keratinocytes containing HPV18 WT and E5KO 
genomes were grown in organotypic raft cultures by 
seeding the keratinocytes onto collagen beds containing 
J2-3T3 fibroblasts. Once confluent the collagen beds 
were transferred onto metal grids and fed from below 
with FCS-containing E media lacking EGF. The cells 
were allowed to stratify for 13 days before fixing with 
4% formaldehyde in E media. The rafts were paraffin-
embedded and 4 μm tissue sections prepared (Propath UK, 
Ltd., Hereford, UK). Cellular DNA synthesis was analysed 
by the addition of 20 μM BrdU to the medium 16-18 hours 
prior to fixation. To detect BrdU-labelled nuclei, sections 
were immunostained with a fluorescein isothiocynate-
conjugated antibody specific for BrdU (Invitrogen). 
Sections were stained with haematoxylin and eosin to 
assess morphology. For analysis of involucrin (SY5, Santa 
Cruz Biotechnology (sc-21748)), cyclin B1 (H-433, Santa 
Cruz Biotechnology (sc-752)), HPV18 E4 (R424, [27]), 
HPV18 L1 (5A3, Novacastra Laboratories), EGFR (R-1, 
Santa Cruz Biotechnology) and KGFR (H-80, Santa Cruz 
Biotechnology) protein expression, the formaldehyde-
fixed raft sections were treated with the sodium citrate 
method of antigen retrieval. Briefly, sections were boiled 
in 10 mM sodium citrate with 0.05% Tween-20 for 
10 minutes. Sections were incubated with appropriate 
antibodies and immune complexes visualized by using 
Alexa 488 and 594 conjugated secondary antibodies 
(Invitrogen). The nuclei were counterstained with the 
DNA stain 4’,6-diamidino-2-phenylindole (DAPI) and 
mounted in Prolong Gold (Invitrogen).
To detect nuclei positive for viral DNA 
amplification, organotypic raft culture sections were 
probed with a biotin-conjugated HPV DNA probe specific 
for the high-risk HPV types [26] using Leica BOND-
Max technology as described by the manufacturer (Leica 
Microsystems, Milton Keynes) and imaged with a light 
microscope (performed by Human Biomaterials Resource 
Centre (University of Birmingham).
Southern blot analysis
Total genomic DNA was extracted from cell culture by 
phenol-chloroform extraction. DNA (5 μg) was treated with 
Dpn1 to digest residual input DNA and either BglII or EcoRI 
to analyse the physical status of the HPV18 genomes. There 
are no BglII sites in the HPV18 genome. The digested DNA 
was analysed on a 0.8% agarose gel and DNA transferred 
to GeneScreen™ nylon membrane. Complete HPV18 
genome was released from the pGEMII backbone vector by 
EcoRI digestion, purified and labelled with [α-32P]-CTP. The 
membrane was incubated with this radiolabelled linear probe 
at 42°C overnight. Following washing the membrane was 
exposed to auto-radiograph film.
High calcium differentiation assay
Untransfected NHK and HPV18 containing 
keratinocytes were grown in complete E media until 90% 
confluent. Media was changed to serum free keratinocyte 
media without supplements (SFM medium, Invitrogen) 
containing 1.8 mM calcium chloride. Cells were 
maintained in this media for between 48 - 72 hours before 
lysis and analysis.
Western blotting
Total protein was extracted from keratinocytes 
in Leeds lysis buffer [56] and resolved by SDS-PAGE 
(10-15% Tris-Glycine), transferred onto Hybond 
nitrocellulose membrane (Amersham biosciences) and 
probed with antibodies specific for phosphorylated 
FRS2α (3861, Cell Signaling Technology), cyclin B1 
(H-433, Santa Cruz Biotechnology), involucrin (SY5, 
Santa Cruz Biotechnology), HPV18 E6 (G-7, Santa Cruz 
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Biotechnology), HPV18 E7 (8E2, Abcam (ab100953), 
AKT (9272, Cell Signaling Technology), phospho-AKT 
Ser473 (D9E, Cell Signaling Technology), HA (HA-7, 
Sigma H9658), cytokeratin 1 (Poly19056, Covance), 
phospho-ERK1/2 (43705, Cell Signalling Technology), 
GAPDH (G-9, Santa Cruz Biotechnology), phospho-
GSK3α/β (9336, Cell Signalling Technology) and 
EGFR (R-1, Santa Cruz Biotechnology). Immunoblots 
were visualized with species-specific HRP conjugated 
secondary antibodies (Sigma) and ECL (Thermo/Pierce).
Retrovirus transduction
pLNCX AKT vectors (Addgene 9005, 9006 [40]) 
were transfected into HEK 293T cells with murine 
retrovirus envelope and GAG/polymerase plasmids 
(kindly provided by Professor Greg Towers, University 
College London) using PEI transfection reagent. After 48 
hours the media was removed from the HEK 293T cells 
and added to keratinocytes for 3 hours. After this time, the 
complete E media was replaced and the cells incubated 
for 16 hours.
Quantitative real-time PCR
Total RNA was extracted from NHK using the 
E.Z.N.A. Total RNA Kit I (Omega Bio-Tek) according 
to the manufacture’s protocol. Total RNA (1 μg) was 
reverse transcribed with a mixture of random primers and 
oligo(dT) primers using the qScript™ cDNA SuperMix 
(Quanta Biosciences) according to instructions. Q-RT-PCR 
was performed using the QuantiFast SYBR Green PCR kit 
(Qiagen) and primers specific to KGFR (Supplementary 
Table 1). The PCR reaction was conducted on a Corbett 
Rotor-Gene 6000 (Qiagen) as follows: initial activation step 
for 10 min at 95°C and a three-step cycle of denaturation 
(10 sec at 95°C), annealing (15 sec at 60°C) and extension 
(20 sec at 72°C) which was repeated 40 times and 
concluded by melting curve analysis. The data obtained 
was analysed according to the ΔΔ Ct method [57] using the 
Rotor-Gene 6000 software. U6 served as normaliser gene.
Analysis of raft staining
Analysis of staining intensities was performed using 
the image J software. Cross sections of the raft sections 
were plotted using the histogram function on the software. 
Histograms represent cross sections from 5 fields of view 
from three independent experiments.
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